Cosmos Health (COSM) to Release Quarterly Earnings on Friday

Cosmos Health (NASDAQ:COSM) is anticipated to issue its results after the market closes on Friday, April 10th. Analysts expect the company to announce earnings of ($0.04) per share and revenue of $18.8210 million for the quarter.

Cosmos Health Price Performance

Cosmos Health stock opened at $0.31 on Friday. Cosmos Health has a 52-week low of $0.28 and a 52-week high of $1.32. The company has a quick ratio of 0.84, a current ratio of 0.99 and a debt-to-equity ratio of 0.25. The firm’s fifty day moving average is $0.38 and its 200 day moving average is $0.61. The company has a market cap of $11.48 million, a price-to-earnings ratio of -0.41 and a beta of 5.33.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Cosmos Health in a report on Wednesday, January 21st. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Cosmos Health has an average rating of “Sell”.

Insider Activity at Cosmos Health

In other Cosmos Health news, CEO Grigorios Siokas purchased 493,495 shares of Cosmos Health stock in a transaction dated Wednesday, January 14th. The shares were purchased at an average cost of $0.45 per share, for a total transaction of $222,072.75. Following the completion of the acquisition, the chief executive officer owned 7,738,474 shares in the company, valued at $3,482,313.30. This represents a 6.81% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders purchased a total of 2,145,143 shares of company stock worth $982,154 over the last quarter. Corporate insiders own 25.10% of the company’s stock.

Hedge Funds Weigh In On Cosmos Health

Large investors have recently bought and sold shares of the business. XTX Topco Ltd grew its position in Cosmos Health by 52.1% in the 4th quarter. XTX Topco Ltd now owns 99,610 shares of the company’s stock valued at $50,000 after acquiring an additional 34,117 shares during the last quarter. Citadel Advisors LLC lifted its position in shares of Cosmos Health by 133.1% during the third quarter. Citadel Advisors LLC now owns 225,507 shares of the company’s stock worth $250,000 after purchasing an additional 128,776 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its stake in shares of Cosmos Health by 260.5% during the fourth quarter. Renaissance Technologies LLC now owns 334,575 shares of the company’s stock valued at $167,000 after purchasing an additional 241,775 shares during the period. Hedge funds and other institutional investors own 12.61% of the company’s stock.

Cosmos Health Company Profile

Cosmos Health Inc manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, Cayman Islands, and Cyprus. It offers medicines, OTC medicines, nutraceutical products, vitamins, minerals and dietary, health care products, medical devices, baby products, and others under the Sky Premium Life and Mediterranation brand names. The company serves wholesale distributors and other healthcare providers, such as clinics, government agencies, independent retail and specialty pharmacies and independent specialty distributors.